Tight glycaemic control is essential for reducing the risk of long-term diabetic complications in people with type I or II diabetes. Intensive blood-glucose control attempts to normalise both pre-and postprandial glycaemia, while avoiding severe hypoglycaemia. A basal insulin, providing a low level of insulin to cover postprandial and overnight fasting periods, is central to intensive blood-glucose control. However, hypoglycaemia, particularly nocturnal hypoglycaemia, is a major treatmentrelated complication of therapy with most basal insulins currently available for use in clinical practice. This is a result of pronounced peaks in absorption, which lead to inappropriate hyperinsulinaemia following evening administration, and especially poorly reproducible pharmacokinetic profiles when injected subcutaneously. Indeed, for many patients and healthcare providers, concern around hypoglycaemia forms a critical barrier to the attainment of tight glycaemic control. Insulin detemir is a novel long-acting analogue of human insulin designed to overcome these practical limitations. Clinical evidence from comparative studies with NPH insulin shows that insulin detemir provides a consistent and clinically relevant reduction in hypoglycaemic risk, especially for nocturnal events, at equivalent or better levels of glycaemic control.
Introduction
Tight glycaemic control, achieved by intensive treatment, is central to reducing the risk of long-term complications of type I and II diabetes. 1, 2 Intensive insulin regimens attempt to achieve 24-h normoglycaemia by replacing insulin activity as close as possible to the physiological insulin secretion profile of healthy individuals. However, implementation of such regimens increases the risk for severe hypoglycaemia, especially nocturnal episodes. 1, 3 In the DCCT, despite efforts to reduce the risk of hypoglycaemia, the incidence of severe hypoglycaemia with intensive treatment (multiple daily injections of insulin) was three times higher than with conventional treatment (once/twice daily insulin injections) 1 at any level of glycaemic control 4 and persisted over the average 6.5 y of follow-up in the intensively treated group. 5 Therefore, an inverse correlation exists between glycaemic control and the risk of hypoglycaemia ( Figure 1 ), and the gradient of this correlation increases as insulin therapy is intensified.
Is hypoglycaemia an inevitable accompaniment to improved glycaemic control?
Hypoglycaemia, particularly nocturnal, is a major treatmentassociated complication of diabetes. 3, 6, 7 Indeed, it is considered to be the main barrier to the effective management of diabetes. 8, 9 Mild episodes of hypoglycaemia are associated with symptoms of sweating, palpitations, tremor, loss of concentration and confusion and are unpleasant for the patient. Severe episodes can cause convulsions and coma, and are especially feared by patients. 10 Nocturnal hypoglycaemia is common with the use of insulin regimens and the threat of this metabolic problem may potentially have serious consequences. During the DCCT, 43% of severe hypoglycaemic episodes occurred during sleep. 3, 5 A basal insulin supply, supplemented by multiple preprandial injections of insulin, is central to intensive bloodglucose control in both type I and II diabetes. An ideal basal insulin would provide a prolonged, constant and consistent activity profile when administered subcutaneously. Conventional basal insulins, such as NPH insulin, are limited by high variability in blood-glucose lowering responses after subcutaneous injections. Peaks in insulin absorption occurring a few hours after subcutaneous administration can, on evening administration, coincide with nocturnal periods when insulin requirements are low, resulting in hypoglycaemia. Thus, the pharmacokinetic profiles of conventional basal insulins, and the unpredictable nature of these profiles, may result in occasions where the nature of basal insulin replacement is quite inappropriate. The development of new insulin analogues that are more consistent and less variable than existing insulins and with a prolonged duration of action holds the promise of improving control without the attendant risk of hypoglycaemia.
Maintaining control and reducing the risk of hypoglycaemia
The pharmacokinetic profile of insulin detemir, a new basal insulin analogue, reveals a greater reproducibility than conventional long-acting insulins, 11 and compared with NPH insulin it has a smooth time action profile. 12 Thus, insulin detemir has the potential to improve the balance between hypoglycaemic risk and improved metabolic control. Indeed, several studies have shown that insulin detemir is associated with a lower risk of nocturnal hypoglycaemia than NPH insulin, with equivalent or better glycaemic control. [13] [14] [15] [16] A significant reduction in risk for nocturnal hypoglycaemia was clearly demonstrated in a 6-month, parallel group, open-label study in 749 people with type I diabetes, in which patients were randomised to once-daily therapy with either insulin detemir or NPH insulin, in a basal-bolus regimen with meal-time human insulin. 13 IDet, 7.60% vs NPH, 7.64%; NS), but insulin detemir dayto-day variation in fasting self-monitored blood-glucose (within-subject variation (s.d.), 3.37 vs 3.78; Po0.001) and prebreakfast plasma glucose levels were significantly lower for patients on insulin detemir than for those on NPH insulin (7.6 vs 9.5 mmol/l, Po0.05). In contrast, the NPH insulin nocturnal blood-glucose profile was characterised by low blood-glucose levels between 0200 and 0400, which rose sharply thereafter reaching high levels on waking. Taken together, these findings show that the effect of insulin detemir was smoother, more stable and longer lasting than that of NPH insulin. A 6-month extension of this study confirmed that insulin detemir continues to offer a clinically meaningful hypoglycaemia advantage over NPH insulin within the context of similar overall glycaemic control during long-term therapy. 16 During the maintenance phase (last 11 months of study), a 22% lower risk of overall hypoglycaemia (relative risk for insulin detemir, 0.78 (0.56-1.08)) and 32% (P ¼ 0.02) lower risk of nocturnal hypoglycaemia was shown in the insulin detemir group compared with the NPH insulin group, and there were fewer events every month (Figure 2 ). At the same time, insulin detemir afforded equivalent glycaemic control to NPH insulin, with baseline-adjusted values of HbA 1c of 7.5370.10 and 7.5970.13%, respectively. It should be noted that an effective reduction in the frequency of hypoglycaemic events will tend to increase HbA 1c , so a relative risk reduction for hypoglycaemia at equivalent HbA 1c represents a clinically important improvement in tolerability:efficacy ratio. The reduced risk for nocturnal hypoglycaemia with insulin detemir compared with NPH insulin is not limited to the above studies; it has been a consistent finding across phase III clinical trials (Figure 3 ). Nocturnal hypoglycaemia is considered to be more indicative of treatment differences in basal insulins than bolus insulins due to the negligible influence of the latter during the night. This is especially the case when rapid-acting insulin analogues are used, which, due to their short duration of action, will contribute little to the nocturnal blood-glucose lowering effect of a basal-bolus regimen. Overnight glucose profiles are therefore highly dependent on the activity of the evening basal injection.
Although the risk reduction for hypoglycaemia with insulin detemir is especially manifest at night, a reduced risk for daytime hypoglycaemic events has also been reported. This may also reflect insulin detemir's less pronounced peak of action and lower intrasubject pharmacokinetic variation than NPH insulin. 17 In an open, randomised crossover study, 59 patients with type I diabetes received treatment for two 6-week periods with once daily insulin detemir or NPH insulin in an optimised basal-bolus regimen. 18 During the last 4 days of each treatment period, mean levels of fasting plasma glucose were slightly lower for insulin detemir than for NPH insulin, yet fewer subjects had hypoglycaemic episodes on insulin detemir (66%) than on Figure 1 Risk of retinopathy and severe hypoglycaemia according to HbA 1c .
As the risk of diabetic complications, shown as increased risk of retinopathy, decreases with improved glycaemic control there is an associated increase in the risk of severe hypoglycaemia.
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NPH insulin (77%) (P ¼ 0.05). The lower incidence of hypoglycaemia on insulin detemir was regardless of the time of day. It should be noted that the studies so far referred to have been parallel group trials in which efficacy was the primary end point. A recently reported crossover study was designed to compare insulin detemir with NPH insulin, with hypoglycaemia as the primary end point. In this randomised, open-label study, 130 patients with type I diabetes were treated with twice daily insulin detemir or NPH insulin with meal-time insulin aspart during two 16-week treatment periods. 19 The risk of overall hypoglycaemia was 18% lower (95% CI for relative risk: 0.73; 0.92) with insulin detemir than with NPH insulin, while the risk of nocturnal hypoglycaemia was 50% lower with insulin detemir (95% CI: 0.38; 0.65). Glycaemic control was comparable between regimens at the end of the treatment periods. HbA 1c decreased by 0.3% with both treatments and was comparable at 7.55% (95% CI: À0.11; 0.11) after 16 weeks, but withinperson variation in self-measured plasma glucose was significantly lower with insulin detemir than with NPH insulin at individual time points (breakfast, lunch and dinner) and in the overall analysis (s.d.: 3.0 vs 3.3, Po0.001). Predictably in light of the hypoglycaemia data, nocturnal plasma glucose excursions to values below 4 mmol/l were significantly smaller in area during treatment with insulin detemir than with NPH insulin (P ¼ 0.03). For children and adolescents with type I diabetes, insulininduced hypoglycaemia is a critical problem in disease management, because at this age, hypoglycaemia is not only more frequent 20, 21 but also there remains concern about permanent sequelae of severe and recurrent hypoglycaemia for the developing brain. 22, 23 In the DCCT study, adolescents had a significantly higher rate of hypoglycaemia than adults in both the conventional (P ¼ 0.025) and intensive (P ¼ 0.004) treatment groups, with no difference in relative risks between treatment groups. 24 A 36% reduction in risk for nocturnal hypoglycaemia with insulin Glycaemic control in people with diabetes C Mathieu S37 detemir compared with NPH insulin (P ¼ 0.01) was demonstrated in children and adolescents with type I diabetes, despite equivalent HbA 1c (mean difference (insulin detemir-NPH insulin) ¼ 0.09 (95% CI: À0.12; 0.29, NS) and lower mean fasting plasma glucose levels (8.44 vs 9.58 mmol/l, P ¼ 0.02) in the insulin detemir group. 25 In this 26-week, open, randomised parallel group study, 347 children and adolescents with type I diabetes received insulin detemir or NPH insulin once or twice daily with premeal insulin aspart.
Further support for the hypoglycaemic advantage conferred during treatment with insulin detemir was clearly demonstrated in an 18-week, randomised, open-label, parallel group study in 595 patients with type I diabetes, in which basal-bolus therapy with insulin analogues (insulin detemir and insulin aspart) was compared with therapy with traditional human insulins (NPH insulin and regular human insulin). 26 The relative risk of nocturnal and overall hypoglycaemia was 55% lower (95% CI: 0.35; 0.58) (Po0.001) and 21% lower (95% CI: 0.63; 0.98) (P ¼ 0.04), respectively, with insulin detemir. Glycaemic control with insulin detemir/insulin aspart was superior to that with NPH insulin/human insulin with respect to HbA 1c levels (7.88 vs 8.11%, mean difference: À0.22% point (95% CI: À0.34; À0.10), Po0.001), self-measured fasting plasma glucose (7.63 vs 8.66 mmol/l, Po0.001) and within-person day-today variation in plasma glucose (s.d. ¼ 2.88 vs 3.12 mmol/l, Po0.001). The reduced risk of hypoglycaemia is likely related to the more stable and predictable plasma glucose levels observed with insulin detemir/insulin aspart treatment as indicated by the reduced day-to-day variability in plasma glucose.
In patients with type II diabetes, hypoglycaemic episodes are less common than in patients with type I diabetes but may still lead to severe and potentially fatal outcomes. Data from the UKPDS, which measured rates prospectively, show that during the first 10 y the proportion of insulin-treated patients experiencing a major hypoglycaemic event per year was 2.3% compared with 0.4-0.6% in patients on oral hypoglycaemic agents. 2 Since the degree of glycaemic control was comparable to that seen in studies of intensive insulin therapy in type I diabetes, 1 the data indicate that the risks of hypoglycaemia are significantly lower in those with type II diabetes but are increased during insulin treatment. A comparative study of insulin detemir vs NPH insulin in patients with type II diabetes demonstrated a 16% relative risk reduction for hypoglycaemia for insulin detemir over NPH insulin (relative risk (insulin detemir/NPH insulin), 0.84 (95% CI: 0.52; 1.36)). 27 While this difference did not reach statistical significance, it should be noted that hypoglycaemic events were relatively uncommon in this study. Similar HbA 1c levels were recorded at study end for patients on insulin detemir or NPH insulin (7.63 vs 7.48%). Both insulins were administered once or twice daily, depending on prestudy regimen, with meal-time insulin aspart. Glycaemic control in people with diabetes C Mathieu
The reduced risk of nocturnal hypoglycaemia associated with insulin detemir may be attributable to the absence of a pronounced peak in activity and/or to its more reproducible absorption, providing little or no variation in blood-glucose lowering activity, following subcutaneous administration. The possibility of a correlation between incidence of hypoglycaemia and within-person variation in fasting blood glucose (FBG) was investigated in a meta-analysis of four phase III studies comparing insulin detemir and NPH insulin in basal-bolus treatment regimen. In these studies, people with type I diabetes were treated with insulin detemir (n ¼ 1336) or NPH insulin (n ¼ 814) in combination with premeal regular insulin or insulin aspart for 16-26 weeks insulin detemir. 13, 26, 28, 29 The mean coefficient of variation (CV) for within-person variation in FBG was significantly lower for insulin detemir across studies (30.9 vs 33.6%, difference: 2.7%, P ¼ 0.001). Furthermore, results of the correlation analysis showed a clear positive correlation (r ¼ 1.02, Po0.001) between the incidence of hypoglycaemia and within-person variation in FBG that was independent of the insulin treatment received. These findings indicate that the reduction in within-subject variability of FBG is a major contributor accounting for about 53% of the reduced risk of hypoglycaemia observed with insulin detemir relative to NPH insulin.
Conclusions
The ultimate aim of therapy for people with type I and II diabetes is to attain normoglycaemia with the goal of preventing the onset or worsening of microvascular and macrovascular complications. However, the tools to achieve this target without increasing the risk of hypoglycaemia have not been available. Administration of NPH insulin is associated with increased risk of hypoglycaemia, especially nocturnal events. Fear of this treatment-related hypoglycaemia has prevented use of aggressive insulin regimens to achieve glycaemic targets. Accumulated evidence suggests that, compared with NPH insulin, insulin detemir provides at least equivalent glycaemic control together with a reduced risk of hypoglycaemia, especially nocturnal events, in patients with type I diabetes. In patients with type II diabetes, equivalent glycaemic control with a trend towards a reduced incidence of hypoglycaemia has also been demonstrated. The implication from this is that it should be possible to titrate the dose of insulin detemir more safely, without increasing the risk of hypoglycaemia, to significantly improve glycaemic control and, as a consequence, reduce the risk of long-term diabetic complications.
